MENU
+Compare
GNOM
ETF ticker: NASDAQ
AS OF
Dec 18, 04:59 PM (EDT)
Price
$9.74
Change
-$0.55 (-5.34%)
Net Assets
75.6M

GNOM stock forecast, quote, news & analysis

Category: @Health
GNOM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
A.I.Advisor
a Summary for GNOM with price predictions
Dec 17, 2024

Momentum Indicator for GNOM turns negative, indicating new downward trend

GNOM saw its Momentum Indicator move below the 0 level on December 12, 2024. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 90 similar instances where the indicator turned negative. In of the 90 cases, the stock moved further down in the following days. The odds of a decline are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for GNOM turned negative on December 13, 2024. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at .

GNOM moved below its 50-day moving average on December 12, 2024 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for GNOM crossed bearishly below the 50-day moving average on December 16, 2024. This indicates that the trend has shifted lower and could be considered a sell signal. In of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where GNOM declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for GNOM entered a downward trend on November 21, 2024. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where GNOM's RSI Oscillator exited the oversold zone, of 31 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where GNOM advanced for three days, in of 282 cases, the price rose further within the following month. The odds of a continued upward trend are .

GNOM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Gilead Sciences (NASDAQ:GILD), Illumina (NASDAQ:ILMN), Moderna (NASDAQ:MRNA), Sarepta Therapeutics (NASDAQ:SRPT), Arrowhead Pharmaceuticals (NASDAQ:ARWR).

Industry description

The investment seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Solactive Genomics Index ("underlying index"). The fund invests at least 80% of its total assets in the securities of the underlying index. The underlying index is designed to provide exposure to exchange-listed companies that are positioned to benefit from further advances in the field of genomic science and biotechnology, as well as applications thereof (collectively, "Genomics & Biotechnology Companies"), as defined by Solactive AG, the provider of the underlying index. The fund is non-diversified.

Market Cap

The average market capitalization across the Global X Genomics & Biotechnology ETF ETF is 11.84B. The market cap for tickers in the group ranges from 87.21M to 120.84B. VRTX holds the highest valuation in this group at 120.84B. The lowest valued company is BLUE at 87.21M.

High and low price notable news

The average weekly price growth across all stocks in the Global X Genomics & Biotechnology ETF ETF was 7%. For the same ETF, the average monthly price growth was 254%, and the average quarterly price growth was 242%. QURE experienced the highest price growth at 8%, while LYEL experienced the biggest fall at -29%.

Volume

The average weekly volume growth across all stocks in the Global X Genomics & Biotechnology ETF ETF was -51%. For the same stocks of the ETF, the average monthly volume growth was -50% and the average quarterly volume growth was -27%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 57
P/E Growth Rating: 68
Price Growth Rating: 59
SMR Rating: 91
Profit Risk Rating: 85
Seasonality Score: -24 (-100 ... +100)
View a ticker or compare two or three
GNOM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published General Information

General Information

Category Health

Profile
Fundamentals
Details
Category
Health
Address
Global X Funds600 Lexington Avenue, 20th FloorNew York
Phone
+1 8884938631
Web
www.globalxfunds.com